华润医药(03320)：华润三九中期股东应占净利润18.15亿元，同比减少24.31%

Core Viewpoint - China Resources Pharmaceutical (03320) reported its subsidiary China Resources Sanjiu's unaudited financial performance for the six months ending June 30, 2025, showing a total revenue of RMB 14.81 billion, a year-on-year increase of 4.99%, while net profit attributable to shareholders decreased by 24.31% to RMB 1.815 billion, with basic earnings per share at RMB 1.09 [1] Financial Performance - Total revenue reached RMB 14.81 billion, reflecting a year-on-year growth of 4.99% [1] - Net profit attributable to shareholders was RMB 1.815 billion, representing a decline of 24.31% compared to the previous year [1] - Basic earnings per share stood at RMB 1.09 [1]